OnKure Therapeutics, Inc. Asset Resilience Ratio
OnKure Therapeutics, Inc. asset resilience ratio. OnKure Therapeutics, Inc. (OKUR) has an Asset Resilience Ratio of 5.51% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can OnKure Therapeutics, Inc. fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of OnKure Therapeutics, Inc. (2021–2021)
Asset resilience ratio of OnKure Therapeutics, Inc. from 2021 to 2021. This chart shows how OnKure Therapeutics, Inc.'s Asset Resilience Ratio has changed over time. Read OnKure Therapeutics, Inc. (OKUR) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down OnKure Therapeutics, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see OnKure Therapeutics, Inc. asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $9.88 Million | 5.51% |
| Total Liquid Assets | $9.88 Million | 5.51% |
Asset Resilience Insights
- Limited Liquidity: OnKure Therapeutics, Inc. maintains only 5.51% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
OnKure Therapeutics, Inc. Industry Peers by Asset Resilience Ratio
Compare OnKure Therapeutics, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
OnKure Therapeutics, Inc. Asset Resilience Ratio by Year (2021–2021)
OnKure Therapeutics, Inc. asset resilience ratio by year from 2021 to 2021. The table below shows the annual Asset Resilience Ratio data for OnKure Therapeutics, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-12-31 | 14.94% | $23.01 Million | $154.02 Million | -- |
About OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatmen… Read more